Kevin A. Auton has a Ph.D in microbial biochemistry and has spent his career (25 yrs) in Life and Medical science companies, developing products for biomedical research and diagnostics and is the named inventor of 7 patents. He founded Aseptika (2007) which develops and markets self-monitoring devices and services for health and wellbeing under the Activ8rlives brand. The Company sells directly to consumers who want to be active, eat well and stay healthy by monitoring their own health but who may also need a little help from their clinicians, family or peer group – what we term eMentoring – to stay on-track. The Company has 35,000 users World-wide and sells its products via Amazon.
The self-management through self-monitoring philosophy is being extended by Aseptika to now include the better management of long-term respiratory conditions and through the Small Business Research Initiative (SBRI) funding through the UK’s National Health Service, it is developing early warning tests to help patients with chronic lung infections of Pseudomonas aeruginosa and their clinicians, detect when another exacerbation is about to take place. The patient will undertake this testing themselves at home – requiring a sophisticated laboratory process to be made as simple as a home-use pregnancy test – which the patient will perform once a day. The test will also be used by clinicians on the hospital ward to confirm when an infection (exacerbation) is under control so that the patient may go home sooner. This will be a step change in the way patients with long-term respiratory conditions such as CF, COPD and non-CF Bronchiectasis are better able to manage themselves at home and reduce the number of hospitalisation events (and their duration) throughout lives. Respiratory disease is growing and is predicted by WHO to be the third largest killer by 2030.
